"The U.S. Food and Drug Administration approved Xiidra (lifitegrast ophthalmic solution) for the treatment of signs and symptoms of dry eye disease, on Monday, July 11, 2016. Xiidra is the first medication in a new class of drugs, called lymphocyt"...
Advise patients that a cataract may occur after repeated treatment with OZURDEX® . If this occurs, advise patients that their vision will decrease, and they will need an operation to remove the cataract and restore their vision.
Intravitreal Injection-related Effects
Advise patients that in the days following intravitreal injection of OZURDEX® , patients are at risk for potential complications including in particular, but not limited to, the development of endophthalmitis or elevated intraocular pressure.
When to Seek Physician Advice
Advise patients that if the eye becomes red, sensitive to light, painful, or develops a change in vision, they should seek immediate care from an ophthalmologist.
Driving and Using Machines
Inform patients that they may experience temporary visual blurring after receiving an intravitreal injection. Advise patients not to drive or use machines until this has been resolved.
Last reviewed on RxList: 11/10/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional Ozurdex Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.